Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
Xiaoyu Zhang(Agilent Technologies (United States)), Zhe‐Sheng Chen(New York College of Traditional Chinese Medicine)
Cited by 48
Related Papers
Microbiota in health and diseases
|Signal Transduction and Targeted Therapy|2022|2.9k
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|385
A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway
|Journal of Medicinal Chemistry|2017|107
Recent advances in biomimetic nanodelivery systems: New brain-targeting strategies
|Journal of Controlled Release|2023|100